Radiation and Cancer Biology
Radiation and Cancer Physics
AMA PRA Category 1 Credits 1.00
CAMPEP Credits: 1.00
MDCB Credits: 1.00
Gregory Gan, MD, PhD
University of Kansas Medical Center
Kansas City, Kansas, United States
We have observed the evolution of spatially fractionated radiotherapy (SFRT) primarily to manage metastatic cancer patients in the palliative care setting. Given recent advances in how SFRT can be delivered, can this therapeutic modality be optimized beyond the palliative care setting? This would allow health care providers an opportunity to advance this treatment into the upfront setting and in combination with targeted or immunotherapy. This panel will bring together a physicist, a biologist and a clinician, who will provide an overview of the field from their unique perspective as well as advancing research and future perspectives where SFRT is moving. First, we will have the physicist discuss the differences between SFRT vs. conventional and how the implementation of proton and FLASH may be utilized with SFRT. Next, we will have a biologist provide their perspective on the biologic advantages of SFRT and how it may be used to enhance the immune response and its impact on normal tissue toxicity. Finally, the clinician will provide perspectives on how this technology could be employed in the palliative setting, in management of oligometastatic disease, with cancer re-irradiation and in rationale combination with therapy. Finally, a discussant will pull all three perspectives from the physicist, biologist and clinician together for the audience.
Speaker: Gregory Gan, MD, PhD – University of Kansas Medical Center
Speaker: Yuting Lin, PhD – University of Kansas Medical Center
Speaker: Yolanda Prezado, PhD – Institut Curie
Speaker: Daniel Ma, MD – Mayo Clinic Alix School of Medicine
Speaker: Gregory Gan, MD, PhD – University of Kansas Medical Center
Speaker: Gregory Gan, MD, PhD – University of Kansas Medical Center